Turning Point Therapeutics (NASDAQ:TPTX) released its quarterly earnings data on Monday. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.04), Fidelity Earnings reports.
Shares of NASDAQ:TPTX traded down $0.62 during mid-day trading on Thursday, hitting $42.92. 2,022 shares of the company traded hands, compared to its average volume of 277,669. The company has a debt-to-equity ratio of 0.01, a quick ratio of 32.35 and a current ratio of 32.35. Turning Point Therapeutics has a 52-week low of $24.21 and a 52-week high of $58.56. The stock’s 50 day moving average price is $37.98.
A number of equities analysts have recently commented on TPTX shares. Wells Fargo & Co raised their price objective on Turning Point Therapeutics from $53.00 to $62.00 and gave the stock an “outperform” rating in a report on Wednesday, September 4th. Wedbush started coverage on Turning Point Therapeutics in a report on Monday, September 9th. They issued an “outperform” rating and a $63.00 price objective on the stock. Guggenheim started coverage on Turning Point Therapeutics in a report on Wednesday, July 24th. They issued a “buy” rating and a $58.00 price objective on the stock. Zacks Investment Research upgraded Turning Point Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, October 10th. Finally, Canaccord Genuity raised their price objective on Turning Point Therapeutics from $53.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday, September 5th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Turning Point Therapeutics presently has an average rating of “Buy” and a consensus target price of $54.56.
In other Turning Point Therapeutics news, CFO Yi Larson acquired 2,222 shares of the company’s stock in a transaction on Tuesday, September 10th. The shares were bought at an average cost of $45.00 per share, for a total transaction of $99,990.00. Also, Director Simeon George acquired 177,777 shares of the company’s stock in a transaction on Tuesday, September 10th. The shares were acquired at an average price of $45.00 per share, for a total transaction of $7,999,965.00. Insiders have acquired a total of 189,999 shares of company stock worth $8,549,955 over the last 90 days.
About Turning Point Therapeutics
Turning Point Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.